Literature DB >> 22538498

The role of cell lines in the study of neuroendocrine tumors.

Simona Grozinsky-Glasberg1, Ilan Shimon, Hadara Rubinfeld.   

Abstract

Cell lines originating from neuroendocrine tumors (NETs) represent useful experimental models to assess the control of synthesis and release of different hormones and hormone-like peptides, to evaluate the mechanisms of action of these agents in target tissues at the cellular and subcellular levels, and to study cell proliferation and tumor development, as well as the effect of different drugs on these complex processes. To date, the understanding of NET biology (with regard to their mechanisms of hormone secretion, cell proliferation and metastatic spread) has been hampered by the lack of appropriate animal models or cell lines for their study. In the present review, we aim to summarize the recent in vitro/in vivo data regarding cell lines derived from NETs which are most frequently employed in experimental neuroendocrinology.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22538498     DOI: 10.1159/000338793

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  16 in total

1.  Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long-Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor.

Authors:  Javier Molina-Cerrillo; Enrique Grande; Teresa Alonso-Gordoa
Journal:  Oncologist       Date:  2019-03-15

2.  The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.

Authors:  Elke Tatjana Aristizabal Prada; Gerald Spöttl; Julian Maurer; Michael Lauseker; Eva Jolanthe Koziolek; Jörg Schrader; Ashley Grossman; Karel Pacak; Felix Beuschlein; Christoph Joseph Auernhammer; Svenja Nölting
Journal:  Endocr Relat Cancer       Date:  2018-06-12       Impact factor: 5.678

Review 3.  Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.

Authors:  E T Aristizabal Prada; C J Auernhammer
Journal:  Endocr Connect       Date:  2017-11-16       Impact factor: 3.335

4.  PI3K inhibitor enhances the cytotoxic response to etoposide and cisplatin in a newly established neuroendocrine cervical carcinoma cell line.

Authors:  Zih-Yin Lai; Hsin-Yueh Yeo; Ya-Tse Chen; Kuo-Ming Chang; Tze-Chien Chen; Yung-Jen Chuang; Shing-Jyh Chang
Journal:  Oncotarget       Date:  2017-07-11

5.  The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.

Authors:  Tobias Hofving; Yvonne Arvidsson; Bilal Almobarak; Linda Inge; Roswitha Pfragner; Marta Persson; Göran Stenman; Erik Kristiansson; Viktor Johanson; Ola Nilsson
Journal:  Endocr Relat Cancer       Date:  2018-03       Impact factor: 5.678

6.  Activation of the ileal neuroendocrine tumor cell line P-STS by acetylcholine is amplified by histamine: role of H3R and H4R.

Authors:  Beatrix Pfanzagl; Diana Mechtcheriakova; Anastasia Meshcheryakova; Stephan W Aberle; Roswitha Pfragner; Erika Jensen-Jarolim
Journal:  Sci Rep       Date:  2017-05-02       Impact factor: 4.379

7.  Osteotropism of neuroendocrine tumors: role of the CXCL12/ CXCR4 pathway in promoting EMT in vitro.

Authors:  Mauro Cives; Davide Quaresmini; Francesca Maria Rizzo; Claudia Felici; Stella D'Oronzo; Valeria Simone; Franco Silvestris
Journal:  Oncotarget       Date:  2017-04-04

Review 8.  Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations.

Authors:  Gabriel Benyomo Mpilla; Philip Agop Philip; Bassel El-Rayes; Asfar Sohail Azmi
Journal:  World J Gastroenterol       Date:  2020-07-28       Impact factor: 5.742

9.  New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines.

Authors:  Andreas Krieg; Sabrina Mersch; Inga Boeck; Levent Dizdar; Eberhard Weihe; Zena Hilal; Markus Krausch; Birte Möhlendick; Stefan A Topp; Roland P Piekorz; Wolfgang Huckenbeck; Nikolas H Stoecklein; Martin Anlauf; Wolfram T Knoefel
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

10.  A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor-guided antibody-drug conjugate: Perspectives on clinical response?

Authors:  Brendon Herring; Jason Whitt; Tolulope Aweda; Jianfa Ou; Rachael Guenter; Suzanne Lapi; Joel Berry; Herbert Chen; Xiaoguang Liu; J Bart Rose; Renata Jaskula-Sztul
Journal:  Surgery       Date:  2019-09-19       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.